Methylation profiles of endometrioid and serous endometrial cancers

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 663-673

  Seeber, Laura M S ^a   Zweemer, Ronald P ^a   Marchionni, Luigi ^b   Massuger, Leon F A G ^c   Smit, Vincent T H B M ^d   Van Baal, W Marchien ^e   Verheijen, René H M ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA METHYLATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROMOTER REGION; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

DNA; DNA MODIFICATION METHYLASE HPAI; SITE SPECIFIC DNA METHYLTRANSFERASE (ADENINE SPECIFIC);

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SITE-SPECIFIC DNA-METHYLTRANSFERASE (ADENINE-SPECIFIC);

EID: 77956356649     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0014     Document Type: Article

References (46)

1. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, Boniver J & Delvenne P 2008 High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 53 525-532.
2. Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, Tsukazaki K & Aoki D 2006 Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncology Reports 16 1189-1196.
3. Baylin SB & Herman JG 2000 DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends in Genetics 16 168-174.
4. Bocker T, Ruschoff J & Fishel R 1999 Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochimica et Biophysica Acta 1423 O1-O10.
5. Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC & Cheung AN 2005 Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. Journal of Molecular Diagnostics 7 8-16. (Pubitemid 40310160)
6. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC et al. 2000 Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics 24 132-138.
7. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY & Pecorelli S 2006 Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynaecology and Obstetrics 95 (Supplement 1) S105-S143.
8. van Diest PJ 2002 No consent should be needed for using leftover body material for scientific purposes. BMJ 325 648-651.
9. Esteller M 2008 Epigenetics in cancer. New England Journal of Medicine 358 1148-1159.
10. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB & Herman JG 1999 hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. American Journal of Pathology 155 1767-1772.
11. Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C & Riva C 2006 The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clinical Cancer Research 12 3329-3336.
12. Guida M, Sanguedolce F, Bufo P, Di Spiezio SA, Bifulco G, Nappi C & Pannone G 2009 Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. European Journal of Gynaecological Oncology 30 267-270.
13. Gylling A, Abdel-Rahman WM, Juhola M, Nuorva K, Hautala E, Jarvinen HJ, Mecklin JP, Aarnio M & Peltomaki P 2007 Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study Gut 56 926-933.
14. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T & Goodfellow PJ 2002 Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecologic Oncology 86 62-68.
15. Ignatov A, Bischoff J, Ignatov T, Schwarzenau C, Krebs T, Kuester D, Costa SD, Roessner A, Semczuk A & Schneider-Stock R 2009 APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Science 101 321-327.
16. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH et al. 2000 Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407 645-648.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J & Thun MJ 2009 Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 59 225-249.
18. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S & Peltomaki P 2008 Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Research 68 4597-4605.
19. Jones PA & Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics 3 415-428.
20. Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M & Inoue M 2003 Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 22 2352-2360. (Pubitemid 36566790)
21. Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB & Lee HP 2006 Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. International Journal of Cancer 118 2168-2171.
22. Kuo LT, Kuo KT, Lee MJ, Wei CC, Scaravilli F, Tsai JC, Tseng HM, Kuo MF & Tu YK 2009 Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. International Journal of Cancer 124 2872-2879.
23. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ & Ellenson LH 1998 PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Research 58 3254-3258.
24. Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, Li AS, Khoo US & Cheung AN 2008 Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. International Journal of Cancer 123 296-302. (Pubitemid 351842013)
25. Macdonald ND, Salvesen HB, Ryan A, Malatos S, Stefansson I, Iversen OE, Akslen LA, Das S & Jacobs IJ 2004 Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer 14 957-965. (Pubitemid 39238185)
26. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, Prat J, Guo M, Herman JG, Matias-Guiu X et al. 2002 Abnormalities of the APC/β-catenin pathway in endometrial cancer. Oncogene 21 7981-7990. (Pubitemid 35430609)
27. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP & Errami A 2005 Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Research 33 e128.
28. Pallares J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasus L, Prat J & Matias-Guiu X 2008 Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Modern Pathology 21 691-699. (Pubitemid 351744834)
29. Pijnenborg JM, Dam-de Veen GC, de Haan J, van Engeland M & Groothuis PG 2004 Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecologic Oncology 94 550-559. (Pubitemid 39024566)
30. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT & Boyd J 1993 Genetic instability of microsatellites in endometrial carcinoma. Cancer Research 53 5100-5103. (Pubitemid 23333372)
31. Risinger JI, Maxwell GL, Berchuck A & Barrett JC 2003 Promoter hypermethylation as an epigenetic component in type I and type II endometrial cancers. Annals of the New York Academy of Sciences 983 208-212. (Pubitemid 36399333)
32. Salvesen HB, Das S & Akslen LA 2000a Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clinical Cancer Research 6 153-159. (Pubitemid 30064988)
33. Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA & Das S 2000b Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clinical Cancer Research 6 3607-3613.
34. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA & Das S 2001 PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer 91 22-26.
35. Scholten AN, Smit VT, Beerman H, van Putten WL & Creutzberg CL 2004 Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100 764-772. (Pubitemid 38176855)
36. Sherman ME, Bitterman P, Rosenshein NB, Delgado G & Kurman RJ 1992 Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. American Journal of Surgical Pathology 16 600-610.
37. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R & Goodfellow PJ 1999 MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Human Molecular Genetics 8 661-666. (Pubitemid 29139981)
38. Stiewe T & Putzer BM 2002 Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death and Differentiation 9 237-245.
39. Suehiro Y, Okada T, Okada T, Anno K, Okayama N, Ueno K, Hiura M, Nakamura M, Kondo T, Oga A et al. 2008 Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clinical Cancer Research 14 3354-3361.
40. Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M & van Diest PJ 2008 Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Annals of Oncology 19 1870-1874.
41. Varley KE, Mutch DG, Edmonston TB, Goodfellow PJ & Mitra RD 2009 Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Research 37 4603-4612.
42. Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr & Broaddus RR 2007 Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Modern Pathology 20 1045-1054.
43. Xiong Y, Dowdy SC, Xue A, Shujuan J, Eberhardt NL, Podratz KC & Jiang SW 2005 Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecologic Oncology 96 601-609.
44. Yang HJ, Liu VW, Wang Y, Tsang PC & Ngan HY 2006 Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6 212. (Pubitemid 44382757)
45. Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS & Mutch DG 2007a Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. Journal of Clinical Oncology 25 2042-2048. (Pubitemid 46972789)
46. Zighelboim I, Goodfellow PJ, Schmidt AP, Walls KC, Mallon MA, Mutch DG, Yan PS, Huang TH & Powell MA 2007b Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clinical Cancer Research 13 2882-2889.